Ну и почитаем тут) Triptans — For moderate to severe symptoms in patients who do not respond to other drugs, triptans can be considered [34]. Sumatriptan (50 to 100 mg orally, 4 to 6 mg subcutaneously, or 5 to 20 mg intranasal solution) and rizatriptan are two selective serotonin agonists that are highly effective in treating migraine headaches. They selectively vasoconstrict brain vessels, but there is a theoretic possibility of vasoconstriction of uteroplacental vessels and increased uterotonic activity [35]. Other triptans can also be used, but frovatriptan and naratriptan are less desirable than other triptans because of their longer half-life, and naratriptan is the least effective triptan. Preparations and dosing are discussed in more detail separately. (See "Acute treatment of migraine in adults", section on 'Triptans'.)
Human experience with triptan exposure during pregnancy primarily involves sumatriptan and has been generally reassuring [31,36,37]. A manufacturer's pregnancy registry for sumatriptan exposure during pregnancy did not find an increased risk of congenital anomalies or early pregnancy loss in 600 exposed pregnant patients, including 514 first-trimester exposures [31]. The pregnancy registry was closed in 2012; additional information may be obtained from the manufacturer (800-336-2176). In a 2015 systematic review of pregnancy outcome following prenatal exposure to triptans (6 studies, 4208 infants), triptan-exposed migraineurs had similar rates of major congenital anomalies, preterm birth, and early pregnancy loss as migraineurs not using triptans [36]. When the triptan-exposed group was compared with the healthy controls, rates of major congenital anomalies and preterm birth were similar, but early pregnancy loss was increased.
UTD
|